Take the chance to meet our experts and explore the latest solutions for wellness and active living in New Jersey April 14–15!
We’re delighted to attending in-cosmetic in Paris, April 14–16, together with Symrise at stand 3E10. Don't miss Christina Vegge, R&D Director at Probi, participating at a panel discussion on April 15.
The probiotic and prebiotic components can interact in one of two ways. With a synergistic synbiotic, the prebiotic substrate selectively nourishes the probiotic strain to enhance its benefit. The result can be an increased targeted health benefit from the combination, compared to the prebiotic and probiotic acting independently.
Probi has entered into a partnership with Clasado Biosciences ("Clasado"), a company renowned for its research and development of prebiotics and the multi-award-winning ingredient Bimuno® GOS.
To assist our customers and partners in capitalizing on the fast-expanding synbiotic market, valued at USD 1.3 billion by 2027[1], Probi and Clasado Biosciences (‘Clasado’) will launch two new scientifically proven synbiotic formulations.
A study recently published highlights the findings from the combination of the two proprietary and well-documented ingredients Bimuno ® GOS and Probi Defendum ® which shown to significantly increase the production of lactate and short-chain fatty acids, specifically butyrate.
The synbiotics by Probi and Clasado combine the most researched probiotic strains with the most comprehensively studied galactooligosaccharide (GOS) prebiotic available on the market. These synbiotic concepts represent truly scientifically backed combinations, offering either a unique and novel gut health position or an overall gut-immune concept.
Concluding a year of decisive and transformative action.
Sales in the first half of the year were down 4% (10% adjusted for currency effects) as a result of weaker underlying demand in the Americas and EMEA. The EBITDA margin was 19% for the first six months of the year.
The start of 2024 has been characterized by a whirlwind of activities and events, largely fueled by our strategic revamp introduced in the later part of 2023.
Probi® was born out of a visionary research project at Lund University, Sweden, whose aim was to discover whether administering specific probiotics to critically ill patients could enhance therapeutic outcomes and improve their chances of recovery.